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This article is one of ten reviews selected from the
Annual Update in Intensive Care and Emergency
Medicine 2017. Other selected articles can be
found online at http://ccforum.com/series/
annualupdate2017. Further information about the
Annual Update in Intensive Care and Emergency
Medicine is available from http://www.springer.
com/series/8901.mic heart disease (IHD), correlating with advancedBackground
Anemia and cardiovascular disease
Approximately seven million people in the United
Kingdom, and 30% of patients admitted to the ICU
have co‐existing cardiovascular disease (CVD) [1–3]
and this proportion may rise as the average age of both
the general population and patients admitted to the
ICU increase. Patients with CVD will have impaired
compensatory mechanisms to enable maximum oxygen
delivery to the tissues in the event of anemia (Fig. 1).
Anemia causes an increase in cardiac output, which
stresses the heart to increase heart rate and stroke
volume. In acute illness, global oxygen demand is
increased, further stressing the heart. This is exacer-
bated by the frequent presence of tachycardia and
hypotension, which reduce blood flow to the coronary
arteries, and by catecholamines that increase myocar-
dial work. Significant left ventricular coronary flow oc-
curs only during diastole and the subendocardial
region is particularly at risk of ischemia because of the
high pressure in the left ventricle [4]. At rest, the myo-
cardium extracts approximately 75% of the oxygen* Correspondence: annemarie.docherty@ed.ac.uk
1Department of Anaesthesia, Critical Care, Pain Medicine, and Intensive Care
Medicine, University of Edinburgh, Edinburgh, UK
2University of Edinburgh, Centre for Inflammation Research, Edinburgh, UK
© Docherty and Walsh. 2017delivered by coronary blood flow [5], and there is there-
fore little reserve when myocardial oxygen consumption is
increased in critical illness. Atheroma‐related flow limita-
tion further compromises myocardial oxygen delivery.Anemia and outcomes in patients with cardiovascular
disease
Anemia is associated with worse outcomes in patients
with CVD, both in terms of severity of illness, and
mortality. Anemia is a significant risk factor in ische-
IHD, chronic heart failure, rhythm disturbance and
higher mortality rate in comparison to non‐anemic pa-
tients [6]. Anemia is also an independent predictor of
major adverse cardiovascular events in patients across
the spectrum of acute coronary syndrome (ACS) [7].
Anemia in heart failure is associated with impaired
functional capacity and cardiac function, renal dys-
function, increased rate of hospitalizations and poor
prognosis [8]. However, these studies are all observa-
tional, and the direction of causality is difficult to
ascertain – anemia may cause the worse outcomes, or
it may be a reflection of the severity of the underlying
chronic disease. It therefore follows that correction
with red blood cells (RBCs) may not improve patient
prognosis.Evidence from transfusion trials
All major RBC transfusion trials have compared re-
strictive with liberal transfusion strategies based on
higher versus lower hemoglobin thresholds for transfu-
sion [9–13]. Trials based in the ICU have shown that a
more restrictive transfusion threshold of 7.0 g/dl is as
safe as a more liberal threshold for the general ICU
population [9, 11, 14]. A recent systematic review did
not find any association with mortality, overall morbid-
ity or myocardial infarction when comparing restrictive
transfusion strategies with liberal transfusion strategies;
Fig. 1 The impact of chronic severe anemia on myocardial function. LV: left ventricular; AVP: arginine vasopressin; RAA: renin-angiotensin-aldosterone;
GFR: glomerular filtration rate. Reproduced from [50] with permission
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Cochrane review indicated that restrictive transfusion
strategies were not associated with an increased rate of
adverse events (mortality, cardiac events, stroke, pneu-
monia and thromboembolism) compared with liberal
transfusion strategies. Restrictive transfusion strategies
were associated with a reduction in hospital mortality
but not in 30‐day mortality [16]. A review published in
2014 using restrictive hemoglobin transfusion triggers
of 7 g/dl showed reductions in in‐hospital mortality,
total mortality, rebleeding, ACS, pulmonary edema,
and bacterial infections compared with liberal transfu-
sion [17].
However, these trials were based in general ICU co-
horts, and there is the risk of practice misalignment,
whereby inclusion of heterogeneous populations in
trials can mask potentially divergent effects in sub-
populations [18]. Both of the major transfusion trials
in ICUs had underpowered pre‐defined subgroups
that suggested that a more liberal transfusion thresh-
old may be beneficial in patients with CVD [9, 11].
Evidence is also limited by the under‐representation
of patients with CVD in trials. Observational studies
suggest the prevalence of CVD in ICU patients is
around 30% [1, 3]; however patients with CVD
accounted for only 20% of patients recruited to the
Transfusion Requirements in Critical Care (TRICC)
trial compared with 29% of patients excluded [9], and
only 14% of patients recruited to the Transfusion
Requirements in Septic Shock (TRISS) trial [11]. A
trial undertaken in patients presenting with acute
gastrointestinal bleeding trial excluded all patients
with significant CVD [12].Evidence in patients with co‐existing cardiovascular
disease
There have been few trials aimed specifically at transfu-
sion thresholds in critically ill patients with co‐existing
CVD. Two recent systematic reviews in cardiac surgery
[19] and in perioperative transfusion practice (including
cardiac surgery) [20] reported higher mortality with a re-
strictive transfusion threshold. Our systematic review
[21] found only 11 blood transfusion threshold ran-
domized controlled trials (RCTs) that included patients
with co‐existing CVD, either as the whole population
[10, 22–24], as a pre‐defined subgroup [9, 11, 25] or as
a high proportion of patients [14, 26–28]. We found no
evidence of a difference in 30‐day mortality between re-
strictive and liberal transfusion thresholds. However,
we found an increased risk of new ACS in patients with
co‐existing CVD who were randomized to a restrictive
blood transfusion threshold (Figs. 2 and 3). The re-
strictive transfusion threshold for most of the included
trials was 8 g/dl compared with a liberal transfusion
threshold of 10 g/dl. These trials do not, therefore, pro-
vide high quality evidence that the widely recom-
mended ‘default’ transfusion trigger of 7 g/dl is as safe
as higher thresholds for preventing ACS in patients
with CVD. There was no difference in the incidence of
pulmonary edema between restrictive and liberal
thresholds; however pulmonary edema can result from
both transfusion‐related circulatory overload and ACS,
and these were not reported separately in the different
trials.
Current guidelines reflect the paucity of evidence
in patients with co‐existing cardiovascular disease
(Table 1).
Fig. 2 Systematic review: Blood transfusion thresholds in patients with cardiovascular disease (CVD). Forest plot showing risk ratios for 30‐day
mortality, and risk of bias assessment for each study. *Additional risk of bias assessed as to completeness of patients recruited into clusters (this
was graded as low risk). Modified from [21] with permission
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Audits of blood transfusion practice in the UK have con-
sistently shown that around 20% of blood product usage
is outside guideline recommendations [29]. This vari-
ation in practice was evident in an analysis of the ABLE
trial (Age of transfused blood in critically ill adults),
which found that the presence of co‐existing CVD modi-
fied transfusion thresholds [30].
Future trial design
A pragmatic RCT of restrictive versus liberal blood
transfusion thresholds in patients with CVD with mor-
tality as a primary outcome is likely to encounter the
same difficulties as previous trials. In order to find a 5%
reduction in mortality (32 to 27%, 90% power), a two‐
arm trial would require nearly 2,000 patients. Within
this population will be patients with differing severity
of cardiovascular disease, and differing severity of acute
illness, and there is again the risk of practicemisalignment. Using the ‘PICO’ model, we address
some of the difficulties a future trial might encounter
and offer some potential solutions.
Population
Critically ill patients with co‐existing CVD are not all
the same. There is a spectrum of severity of both CVD
and critical illness, and it follows that the balance of
risks and benefits of transfusion may change along this
spectrum.
One approach could be to limit the trial population to
the highest risk group, such as those with high severity
of illness scores at presentation to the ICU (e. g., APA-
CHE II score > 19), or those with known coronary artery
disease. This would mean that we are focusing on the
group in which we are most likely to see a difference in
outcome between restrictive and liberal thresholds. In
addition to this, these patients have high hospital and
longer‐term mortality, which may make trial numbers
Fig. 3 Systematic review: Blood transfusion thresholds in patients with cardiovascular disease (CVD). Forest plot showing risk ratios for adverse
cardiovascular events and risk of bias assessment for each study. Modified from [21] with permission
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could say with confidence that patients with CVD do
not benefit from higher transfusion thresholds. However,
if there is a benefit in this high‐risk group (and from
previous trials, we have seen no benefit in patients with-
out CVD), we would be unable to recommend practice
for the low‐risk CVD group – patients who are either
less critically ill or have milder co‐existing CVD. A sub-
sequent trial would potentially need to be undertaken in
this group.Table 1 Table of guidelines for red blood cell transfusion in patient
Organization Year Recommen
for general
British Committee for Standards
in Haematology [38]
2013 7.0 g/dl, tar
7.0–9.0 g/d
NICE: National Institute for Health
and Clinical Excellence [51]
2015 7.0 g/dl, tar
7.0–9.0 g/d
Association of Anaesthetists of Great Britain
and Ireland [52]
2016 7.0 g/dl
American Association of Blood Banks (AABB) [53] 2016 7.0 g/dl
ACS acute coronary syndrome, CVD cardiovascular disease, Hb hemoglobinIt is physiologically appealing to design a trial that
individualizes transfusion based on patient risk of
mortality or ACS. Those patients at high risk would
be transfused at a higher threshold than those at
lower risk. Significant work would need to be carried
out modelling risk in this population to inform the
trial design, and observational studies are ongoing
[31]. An adaptive trial design, allowing the risk algo-
rithm to be informed by previous participants in the
trial would reduce the risk to patients of beings with cardiovascular disease
dation Recommendation for CVD
get
l
Stable angina should have a Hb maintained > 7.0 g/dl
get
l
ACS: transfusion threshold of 8.0 g/dl, target of 8.0–10.0 g/dl
Chronic: further research
Uncertainty remains for patients with ischemic heart disease,
higher thresholds (8.0 g/dl) may be appropriate
Patients with symptoms or a Hb level of 8.0 g/dl or less
Docherty and Walsh Critical Care  (2017) 21:61 Page 5 of 8randomized to a harmful threshold and would be
more cost‐effective.
Intervention
RBC transfusion is current standard practice for correct-
ing anemia in critically ill patients, and it would be lo-
gical to continue this in a future trial. Iron therapy plus
or minus erythropoietin would be another potential
intervention. There is a functional iron deficiency in crit-
ical illness and a theoretical increased risk of bacterial
infection with the use of iron, and although there is an
ongoing trial into intravenous iron in critical illness [32],
use of iron or erythropoietin is not standard during
the acute phase of critical illness. Previous large trials
of erythropoietin have not shown efficacy for signifi-
cantly reducing RBC transfusions and/or increasing
hemoglobin by clinically relevant amounts [33]. A
limitation of both iron and erythropoietin is their slow
impact on erythropoiesis and hemoglobin level in the
context of acute illness. It seems likely that RBC trans-
fusion will remain the therapy of choice for acutely in-
creasing hemoglobin concentration in critical illness.
Comparator
Previous transfusion trials have all compared liberal with
restrictive transfusion hemoglobin thresholds. There are
limitations in using hemoglobin, given that the concen-
tration is significantly affected by fluid resuscitation,
however this is a pragmatic approach which is reprodu-
cible and routinely measured. In a population in which
patients are not sedated and ventilated, an alternative
could be to transfuse based on symptomatology, or po-
tentially anaerobic threshold, but this is unlikely to be
feasible in the ICU.
Thresholds have varied between trials (restrictive 7.0–
9.7 g/dl, liberal 9.0–11.3 g/dl [21]), with overlap between
restrictive thresholds in some trials and liberal in others.
The larger the difference in thresholds, the more likely a
difference will be shown, and a trial of 7 g/dl (current
practice excepting ACS) vs 90 g/l would need fewer pa-
tients than 7.5–8.0 g/dl vs 9.0 g/dl. Clinicians need equi-
poise, and if clinicians are unwilling to randomize
patients with CVD to a low threshold of 7.0 g/dl then a
higher threshold must be agreed on, otherwise high‐risk
patients may be excluded from the trial.
Outcomes
Mortality
The majority of blood transfusion threshold trials have
used 30‐day mortality as their primary outcome. There
are many causes of mortality in critically ill patients and
it is difficult to argue that mortality during the first few
days of critical illness is anything other than a result of
the severity of presenting illness. A 10–20% difference inhemoglobin concentration seems to lack biological
plausibility to alter this substantially. Longer‐term mor-
tality may be a more appropriate endpoint either in iso-
lation or combination with measures of quality of life.
Acute coronary syndrome
ACS is an appropriate outcome for blood transfusion tri-
als, particularly in patients with co‐existing CVD. How-
ever, diagnosis of ACS in critically ill patients is not
straightforward. Standard diagnosis comprises patient
symptoms and signs, evidence of ischemia on the elec-
trocardiogram (EKG), and a rise and fall pattern of car-
diac biomarker (usually troponin I or troponin T) [34].
Standard symptoms are often masked by sedation, delir-
ium or analgesia. EKGs are not performed routinely and
there is significant interobserver variability [35]. Tropo-
nin release is prevalent in the critically ill [1, 36] and
there are multiple causes. Potential cardiac mechanisms
include increased thrombogenicity leading to coronary
plaque rupture and thrombosis (type I myocardial in-
farction) or underlying critical coronary artery disease
leading to an oxygen supply/demand imbalance (type II
myocardial infarction) [34]. However, elevated troponin
is also recognized in sepsis, end‐stage renal disease,
acute exacerbations of chronic obstructive pulmonary
disease (COPD) and acute intracerebral pathology [37].
This finding may be as a result of underlying cardiac dis-
ease, but there is also evidence of troponin release as a
result of direct toxicity from cytokines, stretch‐mediated
troponin release, or ongoing subclinical myocardial in-
jury due to uremia and impaired excretion [37]. Our sys-
tematic review found that cardiovascular events were
diagnosed by unblinded clinicians in a third of trials, and
that the criteria for the diagnosis of myocardial infarc-
tion were inconsistent (Table 2), and this resulted in a
low GRADE quality of evidence [21]. The diagnosis of
ACS in high‐risk patients who are unable to communi-
cate their symptoms, have non‐specific EKG changes,
and multiple causes for troponin elevation is challenging
and often arbitrary. Before we are able to use ACS as an
objective endpoint, we need to be able to diagnose its
presence or absence with accuracy and precision.
Duration of mechanical ventilation
Weaning consists of liberation from mechanical ventila-
tion and extubation. Patients with CVD may develop
myocardial ischemia associated with the increased sym-
pathetic activation associated with difficulty weaning
from the ventilator. Studies have suggested an associ-
ation between anemia and failure to wean, and between
RBC transfusion and reduction in the work of breathing
[38]; however this is not a consistent finding. Transfu-
sion in anemic patients with CVD prior to weaning
could potentially reduce the incidence of ACS, as well as
Table 2 Acute coronary syndrome (ACS) in patients with co‐existing cardiovascular disease in critical care blood transfusion
threshold trials. Diagnosis made by Investigator (I) or Clinician (C)
Author, year Population Blinded y/n Diagnosis of ACS Incidence of
new ACS
de Almeida, 2015 [27] Major abdominal cancer surgery Y (I) Clinical symptoms suggesting myocardial ischemia
with ≥ 1 of the following:
increase/decrease in cTnI (≥1 value > 99th
centile upper reference limit);
EKG changes: new Q waves, ST elevation, new LBBB;
Image‐based evidence of new loss of viable myocardium
R: 0/22
L: 0/12
Hebert, 1999 [9] General ICU ? (I) Unclear *
Holst, 2014 [11] Septic shock Y (I) Symptoms, EKG signs, or elevated biomarker levels
resulting in an intervention
R: 6/75
L: 2/66
Walsh, 2013 [14] Older, mechanically ventilated N (C) Troponin rise, new EKG change R: 1/17
L: 0/15
*All complications, including shock, myocardial infarction, unstable angina and cardiac arrest, with the exception of acute pulmonary edema (9 vs. 18%; p < 0.01),
were comparable in both groups (p > 0.05). LBBB left bundle branch block, R restrictive, L liberal, Tn troponin, EKG electrocardiogram
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lished ICU trials have commented on duration of mech-
anical ventilation specifically for patients with CVD.
Data regarding ICU and hospital length of stay are also
scarce (Table 3).
Health-related quality of life (HRQOL)
There are few data regarding the prevalence and time
course of anemia after intensive care. One study showed
that 77% of patients were still anemic at hospital dis-
charge and that nearly half the patients who were in the
ICU for seven or more days had hemoglobin concentra-
tions < 10.0 g/dl [39]. In a study looking at patients
mechanically ventilated > 24 h and discharged from ICU
with hemoglobin concentrations < 10.0 g/dl, half the pa-
tients were still anemic at six months [40]. The anemia
was predominantly normochromic and normocytic, con-
sistent with ongoing inflammation, inappropriate
erythropoietin response and poor marrow RBC produc-
tion, although the contribution of iron deficiency is diffi-
cult to ascertain in these states. These patients had a
reduced mean SF‐36 score at both 3 and 6 months com-
pared to the normal population. Studies looking at
HRQOL for anemia and other chronic disease such as
malignancy [41] and end‐stage renal disease [42] consist-
ently show an association between hemoglobin concen-
trations and HRQOL. Fatigue is a prevalent symptomTable 3 Duration of mechanical ventilation, length of stay in
ICU/hospital (LOS) in patients with co‐existing cardiovascular
disease in critical care blood transfusion threshold trials
Author, year Population ICU LOS Hospital
LOS










R restrictive, L liberalamong survivors, and many of the physical features of
the post‐ICU syndrome are typical of anemia [43]. How-
ever, the causal association between anemia and fatigue,
and reduced HRQOL, in this patient group are not well
studied. Equally, there are no high quality studies explor-
ing whether interventions to treat and correct anemia,
whether with RBC transfusion or non‐transfusion inter-
ventions such as iron or erythropoietin, can modify these
important outcomes.Cost‐effectiveness
The cost of a unit of blood is around £120 in the UK,
but this does not take into account the complications
avoided and complications arising from transfusion.
Evaluation of the cost‐effectiveness of RBC transfusion is
essential. The combination of very high hospital costs
for critically ill survivors [44] and low HRQOL during
the months following survivorship means that the loss of
quality‐adjusted life years (QALYs) is substantial follow-
ing critical illness. The rationale for blood transfusion is
to decrease both deaths and complications, such as new
ACS, which might impact further on quality of life, thus
improving HRQOL and cost‐effectiveness. Few com-
pleted ICU studies have included health economic evalu-
ations. Cost‐effectiveness analysis of the Transfusion
Indication Threshold Reduction (TITRe) II blood trans-
fusion threshold in cardiac surgery trial found no clear
difference between restrictive and liberal arms up to
three months after surgery [45]. Hemoglobin concentra-
tion remained different at hospital discharge in the Re-
strictive and Liberal Transfusion Strategies in Intensive
Care (RELIEVE) trial [14], suggesting that longer term
exposure to anemia and its effect on HRQOL is poten-
tially important for survivors. It seems logical for future
transfusion trials during critical illness to include an eco-
nomic evaluation in addition to measuring clinical out-
comes, especially in exploring the hypothesis that
Docherty and Walsh Critical Care  (2017) 21:61 Page 7 of 8treating anemia might improve quality of life among
survivors.
Future areas for research
Imaging
The mechanism of troponin release in critically ill pa-
tients with cardiovascular disease is not yet fully under-
stood and the relative contribution of ischemic versus
inflammatory injury is unknown. This has potentially
important therapeutic implications. At present, imaging
is mainly limited to bedside transthoracic echocardiog-
raphy (TTE) due to concerns regarding transferring
unstable patients to isolated locations such as the com-
puted tomography (CT) scanner or for angiography.
Standard TTE is technically more difficult in these pa-
tients, and has only moderate diagnostic accuracy.
Strain echocardiography
Strain TTE, is a relatively novel imaging technique and
describes the lengthening, shortening or thickening, also
known as regional deformation, of the myocardium [46].
It uses the unique ‘speckle’ pattern visible in the myocar-
dium on routine echo images. It follows the movement
of blocks of speckle pattern over time frames and is able
to capture longitudinal, circumferential and radial strain
(rate of deformation). This algorithm results in objective
analyses of myocardial function, and is more sensitive
than standard TTE evaluation of left ventricular func-
tion. It has been successfully used to demonstrate left
ventricular dysfunction in septic patients in critical care
[47], and stress cardiomyopathy in patients with sub-
arachnoid hemorrhage [48].
Cardiac magnetic resonance
Cardiac magnetic resonance is another non‐invasive im-
aging technique that allows for accurate visualization of
tissue changes in patients with acute myocardial disease.
In the context of troponin elevation in critical illness, it
is of particular value in distinguishing myocardial infarc-
tion from other myocardial abnormalities such as myo-
carditis, due to the ability to distinguish between
subendocardial and other patterns of fibrosis. Cardiac
magnetic resonance is able to detect the increased tissue
edema in acute myocardial infarction that lasts up to five
weeks and the scar from myocardial necrosis [49]. This
means that patients would be able to be scanned in the
recovery period for troponin elevations that occurred in
acute critical illness.
Blood transfusion in recovery from critical illness
Given the long trajectory of anemia in critical care survi-
vors, another important area to study is the impact of
blood transfusion in patients once they have recovered
from their critical illness. It would be possible to look atboth physiological parameters and patient HRQOL before
and after RBC transfusion. Continuous pulmonary exer-
cise testing (C‐PEX) can give an objective assessment of
anaerobic threshold, as well as monitor for ischemia by
EKG monitoring. Important patient outcomes, such as fa-
tigue and breathlessness, can be explored with qualitative
patient interviews or more structured questionnaires.
Conclusion
There is biological plausibility that patients with CVD
may benefit from higher transfusion thresholds than pa-
tients without CVD. Evidence from a systematic review
and meta‐analysis in this population suggest that there is
no difference in 30‐day mortality, but there is an in-
creased risk of ACS in patients with CVD who were ran-
domized to a restrictive transfusion threshold compared
with a more liberal threshold. We suggest that a more
liberal transfusion threshold (>80 g/l) in this population
should be used until a high‐quality trial including end-
points for longer term mortality, ACS, quality of life and
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